Moreover, END seems to induce preferential metabolic benefits characterized by prevention of hyperglycemia, hyperinsulinemia, and improvements in markers of liver damage (AST/ALT), which were paralleled by further increases in muscle HMW adiponectin and normalization of the mRNA levels of direct and indirect downstream effectors of the protein observed after this type of training. The gene discussed is ADIPOQ; the disease is Hyperglycemia.